chronic%20lymphocytic%20leukemia
CHRONIC LYMPHOCYTIC LEUKEMIA

Chronic lymphocytic leukemia (CLL) is a malignant, chronic lymphoproliferative disorder characterized by proliferation and accumulation of monoclonal B-cells in the bone marrow, peripheral blood, lymph nodes, liver and spleen.

It is the most common form of adult leukemia in the Western world but rare in Asians.

Exact etiology is unknown but usually associated with genetic aberrations and lesions.

 

Chronic%20lymphocytic%20leukemia Signs and Symptoms

Introduction

  • The most common form of adult leukemia in the Western world but less common in Asians

Definition

  • A chronic lymphoproliferative disorder characterized by progressive accumulation of monoclonal B-cell lymphocytes found in the blood and bone marrow

Pathophysiology

  • Commonly associated genetic aberrations include:
    • p53 tumor suppressor gene mutation
    • Chromosomal deletions (eg chromosome 17p, chromosome 11q, chromosome 13q)
    • Chromosomal alteration (trisomy 12)

Signs and Symptoms

  • Enlarged lymph nodes
  • Systemic symptoms: Tiredness, fever, night sweats, weight loss
  • Symptoms of anemia or infection

Risk Factors

  • Chemical exposure
  • Family history - 1st-degree relatives (6- to 9-fold increased risk)
  • Race - higher incidence in Caucasians compared to African Americans and Asians
  • Gender - increased incidence in men compared to women
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 08 Jan 2021
Combining the anti-PD-1 antibody sintilimab and a bevacizumab biosimilar significantly improves survival compared with the standard treatment of sorafenib in the first-line setting for patients with advanced, unresectable hepatocellular carcinoma (HCC), according to the ORIENT-32 study presented at ESMO Asia 2020.
Dr Margaret Shi, 5 days ago

Cancer patients at are an increased risk of severe coronavirus disease 2019 (COVID-19) and should be positioned at high priority for vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) regardless of age, according to statements issued by the European Society for Medical Oncology (ESMO).